Tiny study probes COVID antibodies in cystic fibrosis patients
NCT ID NCT05074680
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study followed 5 people with cystic fibrosis over two years to track COVID-19 antibodies from infection or vaccination. Researchers collected blood samples every six months to see how antibodies develop and last. The goal was to understand if people with CF have different immune responses to COVID-19.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help explain why some people with cystic fibrosis may have milder COVID-19 and guide better care.
- What could go wrong
- This is a very small observational study (5 participants) that only measures antibodies, not clinical outcomes. Results may not apply to all people with cystic fibrosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
5 people
The number who actually took part.
- Started
-
Feb 2022
- Finished
-
May 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Consenting people (signed informed consent by participant or parent/caregiver in case of children \<14 years) with cystic fibrosis of any age, genotype, transplant status and disease severity will be eligible to participate in the study. The study population is expected to be representative of the general CF population.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: • Consenting people (signed informed consent by participant or parent/caregiver in case of children \<14 years) with cystic fibrosis of any age, genotype, transplant status and disease severity Exclusion Criteria: * Refusal to give informed consent * Contraindication to venepuncture. Participants already enrolled in a clinical trial are eligible for enrollment in this study. Inclusion in CAR-CF should not preclude enrollment in other observational clinical trial studies or clinical trials of an investigational medicinal product (CTIMP).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cystic fibrosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Children's hospital Bern
Bern, 3010, Switzerland
-
University Children's hospital, Zürich
Zurich, 8032, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Device-Preserved donor lungs boost transplant success?
- Can a simple questionnaire reveal why some cystic fibrosis patients skip physiotherapy?
- Cystic fibrosis diabetes: do gut hormones and genes hold the key?
- Can a special lung scan catch cystic fibrosis damage earlier than standard tests?
- Can a pill replace the liquid? testing a new form of cystic fibrosis drug
- Triple therapy under the microscope: does it transform cystic fibrosis care?